OTLKHIGH SIGNALREGULATORY10-K

OTLK received critical FDA feedback in September 2025, resubmitted their BLA for ONS-5010/LYTENAVA, and secured a PDUFA decision date of December 31, 2025, representing a pivotal regulatory milestone for their only approved product.

This represents a make-or-break moment for OTLK, as ONS-5010/LYTENAVA is their sole approved product (currently only in EU/UK) and FDA approval would unlock the crucial U.S. market. The December 31, 2025 PDUFA date creates an immediate binary outcome scenario that will likely determine the company's near-term viability and validates their previous regulatory strategy.

Comparing 2025-12-19 vs 2024-12-27View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows mixed signals with revenue growing strongly 164% to $8.1M, but cash declining 46% to $8.1M, creating potential liquidity concerns. The company's balance sheet improved significantly with total liabilities cut in half and stockholders' equity deficit narrowing by 56%, while a 157% increase in outstanding shares suggests recent equity financing activity. Overall, the financials reflect a company managing cash burn while generating increased revenue, but the declining cash position raises questions about runway through the critical PDUFA decision date.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+7354.7%
$20K→$1.5M

Receivables surged 7354.7% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Debt
Balance Sheet
+552.5%
$165K→$1.1M

Debt increased 552.5% — substantial leverage increase; assess whether deployed for growth or covering losses.

Revenue
P&L
+163.8%
$3.1M→$8.1M

Strong top-line growth of 163.8% — accelerating demand or successful expansion into new markets.

Capital Expenditure
Cash Flow
-84.3%
$2.8M→$437K

Capex reduced 84.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
+56%
-$73.1M→-$32.2M

Equity base grew 56% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Liabilities
Balance Sheet
-50.2%
$101.9M→$50.8M

Liabilities reduced 50.2% — deleveraging improves balance sheet strength and financial flexibility.

Interest Expense
P&L
-49.3%
$3.5M→$1.8M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
-45.9%
$14.9M→$8.1M

Cash declined 45.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-36.6%
$27.4M→$17.4M

Current assets declined 36.6% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-35.5%
$28.8M→$18.6M

Total assets contracted 35.5% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2025-12-19
PRIOR — 2024-12-27
ADDED
As of December 16, 2025, the registrant had outstanding 64,114,399 shares of common stock, par value $0.01 per share.
Currency translations between Swiss Francs, or CHF, and United States dollars provided herein are based on the noon buying rate in New York City for cable transfers in foreign currencies as certified for customs purposes by the Federal Reserve Bank of New York on September 30, 2025, or CHF 0.80 = $1.00.
We do not represent that CHF were, could have been, or could be, converted into United States dollars at such rate or at any other rate.
In September 2025, we conducted a Type A meeting with the FDA at which we received feedback on resubmitting the BLA.
We subsequently resubmitted the ONS-5010/LYTENAVA BLA and have received a Prescription Drug User Fee Act, or PDUFA, goal date of December 31, 2025 for a decision by the FDA; We may need to enter into alliances with other companies that can provide capabilities and funds for the development and commercialization of product candidates.
+7 more — sign up free →
REMOVED
As of December 24, 2024, the registrant had outstanding 24,905,635 shares of common stock, par value $0.01 per share.
dollars provided herein are based on the noon buying rate in New York City for cable transfers in foreign currencies as certified for customs purposes by the Federal Reserve Bank of New York on September 30, 2024, or CHF 0.9015 = $1.00.
We do not represent that CHF were, could have been, or could be, converted into U.S.
Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations; Raising additional capital, including modifications to our existing convertible securities, may cause dilution to our securityholders, restrict our operations or require us to relinquish rights to our technologies or product candidates; We are highly dependent on the success of ONS-5010/LYTENAVA, our only product that has been approved in the EU and UK.
If ONS-5010/LYTENAVA does not receive regulatory approval outside the EU and UK, or is not successfully commercialized, our business may be harmed; We may need to enter into alliances with other companies that can provide capabilities and funds for the development and commercialization of product candidates.
+7 more — sign up free →
MORE REGULATORY SIGNALS
BCHTHIGHBCHT has added extensive PFAS chemical definitions to their 10-K while removing ...
2026-03-31
OMERHIGHOMER achieved FDA approval for YARTEMLEA in December 2025, transforming from a c...
2026-03-31
UNCYHIGHThe FDA issued a Complete Response Letter (CRL) in June 2025 rejecting UNCY's dr...
2026-03-30
NVNOHIGHNVNO received a not-approvable letter from the FDA for its lead product VenoValv...
2026-03-26
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →